RxDoctor Payments Data

Lori Yancey-Ellis, NP

Family · Oneida, TNNPI 1679191829

Payments from drug & device makers

$660in general payments, 2019–2025

Across 26 payments — averaging $25.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$263
  • GSK$209
  • AbbVie$46
  • Pfizer$38
  • Phathom Pharmaceuticals, Inc.$34
  • Novo Nordisk$33
  • plus $38 from 2 others

What the payments were for

  • Food & beverage$660100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$660 in reported general payments places this provider in the 55th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$6,810
Medicare patients
80
Services billed
262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban64$45,981
OzempicSemaglutide13$18,551
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,374
FarxigaDapagliflozin Propanediol11$7,426
Combivent RespimatIpratropium/Albuterol Sulfate15$7,203
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,746
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen125$4,986
Dexlansoprazole DrDexlansoprazole22$3,806
Albuterol Sulfate HfaAlbuterol Sulfate65$1,498
LantusInsulin Glargine,hum.Rec.Anlog11$1,323
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen32$1,129
Omeprazole64$929
Testosterone Cypionate32$776
Lacosamide11$774
Atorvastatin Calcium92$603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$45,98164 claims
Novo NordiskOzempic$33$18,55113 claims
GSKTrelegy Ellipta, Anoro Ellipta$209$18,12032 claims
AstraZenecaFarxiga$263$7,42611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 6,706 family providers in Tennessee.

Other family in Oneida

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →